Literature DB >> 21447729

Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.

Francesco Galimi1, Davide Torti, Francesco Sassi, Claudio Isella, Davide Corà, Stefania Gastaldi, Dario Ribero, Andrea Muratore, Paolo Massucco, Dimitrios Siatis, Gianluca Paraluppi, Federica Gonella, Francesca Maione, Alberto Pisacane, Ezio David, Bruno Torchio, Mauro Risio, Mauro Salizzoni, Lorenzo Capussotti, Timothy Perera, Enzo Medico, Maria Flavia Di Renzo, Paolo M Comoglio, Livio Trusolino, Andrea Bertotti.   

Abstract

PURPOSE: We determined the gene copy numbers for MET, for its transcriptional activator MACC1 and for its ligand hepatocyte growth factor (HGF) in liver metastases from colorectal carcinoma (mCRC). We correlated copy numbers with mRNA levels and explored whether gain and/or overexpression of MET and MACC1 predict response to anti-Met therapies. Finally, we assessed whether their genomic or transcriptional deregulation correlates with pathologic and molecular parameters of aggressive disease. EXPERIMENTAL
DESIGN: One hundred three mCRCs were analyzed. Copy numbers and mRNA were determined by quantitative PCR (qPCR). Thirty nine samples were implanted and expanded in NOD (nonobese diabetic)/SCID (severe combined immunodeficient) mice to generate cohorts that were treated with the Met inhibitor JNJ-38877605. In silico analysis of MACC1 targets relied on genome-wide mapping of promoter regions and on expression data from two CRC datasets.
RESULTS: No focal, high-grade amplifications of MET, MACC1, or HGF were detected. Chromosome 7 polysomy and gain of the p-arm were observed in 21% and 8% of cases, respectively, and significantly correlated with higher expression of both Met and MACC1. Met inhibition in patient-derived xenografts did not modify tumor growth. Copy number gain and overexpression of MACC1 correlated with unfavorable pathologic features better than overexpression of Met. Bioinformatic analysis of putative MACC1 targets identified elements besides Met, whose overexpression cosegregated with aggressive forms of colorectal cancer.
CONCLUSIONS: Experiments in patient-derived xenografts suggest that mCRCs do not rely on Met genomic gain and/or overexpression for growth. On the basis of pathologic correlations and bioinformatic analysis, MACC1 could contribute to CRC progression through mechanisms other than or additional to Met transcriptional upregulation. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447729     DOI: 10.1158/1078-0432.CCR-10-3377

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  57 in total

1.  Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.

Authors:  Inan Olmez; Ying Zhang; Laryssa Manigat; Mouadh Benamar; Breanna Brenneman; Ichiro Nakano; Jakub Godlewski; Agnieszka Bronisz; Jeongwu Lee; Tarek Abbas; Roger Abounader; Benjamin Purow
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

2.  Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer.

Authors:  Manisha Juneja; Katharina Ilm; Peter M Schlag; Ulrike Stein
Journal:  Mol Oncol       Date:  2013-06-06       Impact factor: 6.603

3.  Metastasis-associated colon cancer-1 is a novel prognostic marker for cervical cancer.

Authors:  Lan Guo; Wanggui Lu; Xuan Zhang; Dixian Luo; Hongwen Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 4.  Patient-derived xenograft models for personalized medicine in colorectal cancer.

Authors:  Jun Xie; Yan Lin
Journal:  Clin Exp Med       Date:  2020-02-25       Impact factor: 3.984

5.  Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Authors:  Cristina Basilico; Anna Hultberg; Christophe Blanchetot; Natalie de Jonge; Els Festjens; Valérie Hanssens; Sjudry-Ilona Osepa; Gitte De Boeck; Alessia Mira; Manuela Cazzanti; Virginia Morello; Torsten Dreier; Michael Saunders; Hans de Haard; Paolo Michieli
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

6.  c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases.

Authors:  Mariana Fathy Gayyed; Nehad M R Abd El-Maqsoud; Amr Abd El-Hameed El-Heeny; Mostafa Fuad Mohammed
Journal:  J Gastrointest Oncol       Date:  2015-12

7.  SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival.

Authors:  F Schmid; Q Wang; M R Huska; M A Andrade-Navarro; M Lemm; I Fichtner; M Dahlmann; D Kobelt; W Walther; J Smith; P M Schlag; U Stein
Journal:  Oncogene       Date:  2015-12-21       Impact factor: 9.867

8.  Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.

Authors:  Yuji Piao; Soon Young Park; Verlene Henry; Bryan D Smith; Ningyi Tiao; Daniel L Flynn; John F de Groot
Journal:  Neuro Oncol       Date:  2016-03-09       Impact factor: 12.300

9.  Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice.

Authors:  Xiao-Ping Chen; Xin-Ping Ren; Jian-Yun Lan; You-Guo Chen; Zong-Ji Shen
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

10.  Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis.

Authors:  Keun Hur; Paloma Cejas; Jaime Feliu; Juan Moreno-Rubio; Emilio Burgos; C Richard Boland; Ajay Goel
Journal:  Gut       Date:  2013-05-23       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.